Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 5/20 | 0.42 |
| ▸ | MMP9 | P14780 | 5/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.40 |
| ▸ | MMP13 | P45452 | 4/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16428389 | 0.89 | MAOB (0.44) | MAOBMAOAMMP1MMP9MMP2 | |
| SCHEMBL13337475 | 0.87 | MAOB (0.48) | MAOBMAOAMMP1MMP9MMP2 | |
| SCHEMBL13459402 | 0.84 | MAOB (0.37) | MAOBMAOAMMP1MMP9MMP2 | |
| SCHEMBL2832950 | 0.84 | RAB9A (0.50) | MMP1MMP9MMP2MMP12ALDH1A1 | |
| SCHEMBL25532032 | 0.78 | ADAM17 (0.43) | MAOBMAOAMMP1MMP9MMP2 | |
| SCHEMBL2838283 | 0.77 | NPC1 (0.54) | MMP1MMP9MMP2MMP12ALDH1A1 | |
| SCHEMBL13366219 | 0.76 | KDM4E (0.50) | MAOBMAOAALDH1A1 | |
| SCHEMBL13663882 | 0.74 | TSHR (0.57) | ALDH1A1 | |
| SCHEMBL14117097 | 0.74 | ADAM17 (0.40) | MMP1MMP9MMP2ADAM17MMP13 | |
| SCHEMBL4277702 | 0.72 | ALDH1A1 (0.53) | MAOBMAOAPARP10PARP15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372885-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | MAOB 90/4885MAOA 132/4885MMP1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.